MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Takeda Pharmaceutical Co Ltd ADR

Slēgts

SektorsVeselības aprūpe

14.96 0.4

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.89

Max

15.03

Galvenie mērījumi

By Trading Economics

Ienākumi

-68B

24B

Pārdošana

-32B

1.1T

P/E

Sektora vidējais

34.581

63.778

EPS

0.048

Dividenžu ienesīgums

4.39

Peļņas marža

2.079

Darbinieki

49,281

EBITDA

-4.3B

380B

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

4.39%

2.39%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

47B

Iepriekšējā atvēršanas cena

14.56

Iepriekšējā slēgšanas cena

14.96

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Takeda Pharmaceutical Co Ltd ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 30. janv. 11:02 UTC

Peļņas

Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO -- Update

2025. g. 30. janv. 07:53 UTC

Peļņas

Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO

2025. g. 28. janv. 00:03 UTC

Karstas akcijas

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

2024. g. 31. okt. 07:27 UTC

Peļņas

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update

2024. g. 31. okt. 06:44 UTC

Peļņas

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance

2024. g. 31. jūl. 07:19 UTC

Peļņas

Takeda Pharmaceutical's First-Quarter Profit Rose on Higher Revenue -- Update

2024. g. 31. jūl. 06:29 UTC

Peļņas

Takeda Pharmaceutical Reports Rise in First-Quarter Net Profit on Higher Revenue

2024. g. 17. jūn. 13:34 UTC

Galvenie tirgus virzītāji

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback

2024. g. 13. maijs 11:26 UTC

Galvenie tirgus virzītāji

AC Immunity Shares Soar on Exclusive License Deal with Takeda

2024. g. 9. maijs 07:37 UTC

Peļņas

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update

2024. g. 9. maijs 07:08 UTC

Peļņas

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss

2025. g. 30. janv. 07:12 UTC

Peļņas

Correct: Takeda: U.S. Business Unit President Julie Kim to Become CEO in June 2026, Not June

2025. g. 30. janv. 07:08 UTC

Peļņas

Takeda: U.S. Business Unit President Julie Kim to Become CEO in June

2025. g. 30. janv. 06:42 UTC

Peļņas

Takeda 3Q Rev Y1.144T Vs. Y1.111T >4502.TO

2025. g. 30. janv. 06:40 UTC

Peļņas

Takeda 3Q Net Y23.8B Vs. Net Y105.7B >4502.TO

2025. g. 30. janv. 06:36 UTC

Peļņas

Takeda: to Discontinue Soticlestat Development Program

2025. g. 30. janv. 06:34 UTC

Peļņas

Takeda: Program May Repurchase Up to 1.8% of Outstanding Shares

2025. g. 30. janv. 06:32 UTC

Peļņas

Takeda: To Buy Back Up to Y100B of Own Shares from Feb. 17 to May 31

2025. g. 30. janv. 06:31 UTC

Peļņas

Takeda Pharmaceutical Raises Revenue, Net-Profit Views for FY Ending March

2025. g. 30. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical Sees FY Net Y118.00B

2025. g. 30. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

2025. g. 30. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical Sees FY Net Y118.00B

2025. g. 30. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical Raises FY Dividend to Y196.00

2025. g. 30. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos EPS Y133.71 Vs EPS Y94.10

2025. g. 30. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Pretax Pft Y282.38B Vs Pft Y100.31B

2025. g. 30. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Oper Pft Y417.52B Vs Pft Y224.14B

2025. g. 30. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Rev Y3.53T Vs Y3.21T

2025. g. 30. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

Salīdzinājums

Cenas izmaiņa

Takeda Pharmaceutical Co Ltd ADR Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

14.89 / 15.155Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.